OK to enter
Advance
7/22/03

--2. (Twice Amended) The method of claim 7, wherein the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least 25-fold higher than the binding affinity with which the compound binds to (i) a human α_{1a} adrenergic receptor and (ii) a human α_{1b} adrenergic receptor, and the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT_{1a} receptor.--

--8. (Amended) The method of claim 7, wherein the compound has the structure:



.--

--9. (Amended) The method of claim 8, wherein the compound has the structure:



.--

--10. (Amended) The method of claim 9, wherein the compound has the structure: